The new facility will expand its Elkton site, adding small molecule manufacturing and testing capabilities, as part of a $70 billion U.S. investment beginning in 2025.
The program is designed to accelerate development of therapies addressing major U.S. health priorities, including domestic manufacturing of essential medicines.
The acquisition will expand the company’s downstream processing portfolio with Protein A chromatography technologies to support monoclonal antibody manufacturing.
The acquisition will add nasal spray and sterile dosage expertise to German company LTS Lohmann’s CDMO network in effort to strengthen its U.S. and global operations.
The Switzerland-based injection system manufacturer will establish a new production facility in Holly Springs, North Carolina to strengthen its U.S. supply chain.
The CDMO is advancing construction of a large-scale buffer media facility at its Laupheim headquarters to expand biologics manufacturing capacity and automation.
The Coral Springs site will expand U.S. production of essential respiratory medicines, include research and development, and create more than 200 skilled jobs by 2030.
The CDMO is investing across France, Italy, and India to expand small molecule and antibody-drug conjugate manufacturing capacity and strengthen supply chain resilience.
The Germany-based CDMO has named its Cuxhaven facility a Center of Excellence for Analytical Services to support advanced therapy and biologics programs.
The UK-based CDMO acquired a cell and gene therapy site in Durham, adding commercial-scale viral vector production and fill-finish capacity to its U.S. network.
The CDMO introduced new cytokine and media systems designed to improve scalability, consistency and efficiency in viral vector and cell therapy production.
The Boston-based biotech’s system reportedly streamlines large-scale viral vector production and reduces costs and variability in gene therapy manufacturing.
The $1 billion agreement will add commercial capacity at Thermo Fisher Scientific’s Greenville, North Carolina site to support pneumococcal conjugate vaccines.
The new construction follows a recently launched active pharmaceutical ingredient facility project in Illinois as part of AbbVie’s $10 billion U.S. investment.
The Stirling site upgrade will support commercial sterile production starting in late 2025 with batch sizes of up to 15,000 vials, according to the CDMO.
The Zhunan facility upgrade will add high-potency, advanced delivery liquid-filled capsule capabilities for complex pharmaceutical ingredients by early 2026.